开能健康(300272) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 was CNY 200,922,590.35, an increase of 3.26% compared to CNY 194,571,331.74 in the same period last year[8]. - Net profit attributable to shareholders decreased by 91.90% to CNY 868,225.96 from CNY 10,719,512.96 year-on-year[8]. - Net profit excluding non-recurring items fell by 82.51% to CNY 1,717,238.15 compared to CNY 9,816,497.26 in the previous year[8]. - Basic and diluted earnings per share dropped by 91.85% to CNY 0.0015 from CNY 0.0184 year-on-year[8]. - The company's terminal business and services generated sales revenue of CNY 141.10 million, an increase of 23.19% year-on-year[24]. - Sales revenue from intelligent manufacturing and core components was CNY 53.81 million, a decrease of 22.20% year-on-year[24]. - Other ecological products and services generated sales revenue of CNY 6.01 million, down 44.67% year-on-year[24]. - Total operating revenue for Q1 2020 was CNY 200,922,590.35, an increase of 3.4% compared to CNY 194,571,331.74 in Q1 2019[53]. - Total operating costs for Q1 2020 were CNY 195,493,016.01, up from CNY 181,215,642.27 in the same period last year, reflecting a year-over-year increase of 7.9%[54]. - Net profit for Q1 2020 was CNY 3,019,618.85, a decrease of 74.7% from CNY 11,914,185.57 in Q1 2019[55]. Cash Flow and Assets - Net cash flow from operating activities was negative at CNY -9,012,489.60, a decline of 139.24% from CNY 22,970,088.63 in the same period last year[8]. - Operating cash flow net amount decreased by CNY 31.98 million, a decline of 139.24% year-on-year[23]. - The company's total assets as of March 31, 2020, were CNY 1,717,697,917.56, slightly down from CNY 1,719,732,178.27 at the end of 2019[50]. - Current assets totaled CNY 584,068,102.60, a decrease of 0.5% from CNY 588,793,776.57 at the end of 2019[50]. - The company's total liabilities were CNY 607,090,619.57, down from CNY 614,595,527.00 at the end of 2019[51]. - The total cash and cash equivalents at the end of the period decreased to ¥43,499,238.46 from ¥103,751,418.75, a decline of approximately 58%[67]. - The total cash and cash equivalents at the end of the period decreased to ¥103,419,002.60 from ¥154,244,756.93 at the end of the previous period[64]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 582,794,909[12]. - The largest shareholder, Qu Jianguo, holds 37.86% of the shares, amounting to 220,638,209 shares, with 165,478,657 shares pledged[12]. - The controlling shareholder and actual controller of the company changed to Mr. Qu Jianguo on April 13, 2020, holding 172,456,803 shares, which is 29.59% of the total share capital[26]. - Mr. Qu Jianguo directly holds 220,638,209 shares, accounting for 37.86% of the total share capital, while he has waived voting rights for 40,881,600 shares (7.01%) and 13,450,000 shares (2.31%) under specific commitments[28]. - Zhao Lijun controls a total of 86,795,021 shares, representing 14.89% of the total share capital, through various investment entities[29]. Commitments and Compliance - The company has reported a commitment to maintain at least 24.5% of its shares in Kaineng Environmental, ensuring no voting rights are exercised during shareholder meetings[33]. - The company has established a commitment to avoid any direct or indirect competition with Kaineng Environmental, ensuring compliance with legal regulations and protecting minority shareholders' interests[35]. - The company has outlined a strategy to reduce and standardize related party transactions, committing to fair and reasonable commercial practices[35]. - The company has maintained strict adherence to its commitments, with no violations reported as of the end of the reporting period[35]. - The company is committed to adhering to its promises regarding related party transactions and has not reported any violations[37]. Research and Development - R&D expenses increased by CNY 3.01 million, a rise of 106.82% year-on-year due to ongoing new product development[22]. - Research and development expenses increased to CNY 5,821,025.83, up from CNY 2,814,546.49, representing a growth of 106.5% year-over-year[54]. - Research and development expenses increased to ¥3,709,000.16 from ¥1,780,563.89 in the previous period, indicating a focus on innovation[57]. Changes and Risks - The company has not reported any significant changes in its intangible assets, core competencies, or key technical personnel during the reporting period[26]. - There were no significant changes in the top five suppliers or customers during the reporting period[26]. - The company has not disclosed any major adverse risk factors affecting future operations or significant difficulties faced during the reporting period[26]. - The company did not implement any share repurchase plans during the reporting period[31]. - The company has not forecasted any significant changes in net profit compared to the same period last year[39].